TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

225 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

136 studies on the map

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Emory University, AtlantaMolecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdaleA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) — University of Alabama at Birmingham, BirminghamA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Cedars Sinai Medical Center, Los AngelesNeurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD — Emory Clinic, AtlantaAutologous Stem Cell Transplant for Crohn's Disease — Icahn School of Medicine at Mount Sinai, New YorkA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado SpringsA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Del Sol Research Management, LLC - Site Number: 8400012, TucsonClinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease — Phoenix Children's Hospital, PhoenixA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes — VA Long Beach Healthcare System, Long Beach, CA, Long BeachA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus — Investigative Site, Beverly HillsEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) — Digestive Health Specialsits, DothanCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaAcute Equol Supplementation and Vascular Function in Women With and Without CKD — University of Colorado Anschutz Medical Campus, AuroraA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease — Phoenix Children's Hospital, PhoenixCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Children's Hospital of Philadelphia, PhiladelphiaDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonA Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) — SouthCoast Research Center, Inc., MiamiA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) — Inland Rheumatology Clinical Trials, Inc., UplandStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — GI Alliance, Sun CityA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Woodholme Gastroenterology Associates, Glen BurnieA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) — Wallace & Lee Center, Beverly HillsDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixLY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Valleywise Health Medical Center, PhoenixAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — UCSD Medical Center, La JollaTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetA Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis — Childrens Hospital of Los Angeles, Los AngelesTesting the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease — Weill Cornell Medicine, New YorkThe Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study — University of California, San Francisco, San FranciscoStudy of DISC-0974-201 in Participants With IBD and Anemia — One of a Kind Clinical Research Center, LLC, ScottsdaleMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangeA Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease — Research Site, DecaturPhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Pinnacle Research Group Llc, AnnistonSelenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies — Northwestern University, ChicagoA Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Investigational Site Number: 8400009, EscondidoA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleAmitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease — University of Michigan, Ann ArborA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease — Phoenix Children's Hospital /ID# 255766, PhoenixA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdalePRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San FranciscoA Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis — Phoenix Children's Hospital /ID# 273015, PhoenixOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy. — Colorado Kidney Care Nephrology, DenverA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) — Clinnova Research ( Site 1042), AnaheimAnti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine — Brigham and Women's Hospital, BostonEffects of Stopping Hydroxychloroquine in Elderly Lupus Disease — University of California, Los Angeles, Los AngelesA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Onyx Clinical Research - Site Number: 8400021, PeoriaTreatment of UC With Novel Therapeutics — Brigham and Women's Hospital, Chestnut HillStudy of Novel Therapeutics for Acute Remedy of Colitis — Brigham and Women's Hospital, Chestnut HillA Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis — Children's Healthcare of Atlanta, AtlantaA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast, DothanAquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation — University of Michigan, Ann ArborStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD — Northwestern Memorial Hospital, ChicagoBone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine, The BronxEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — IMC Gulf Coast Gastroenterology, PC, FairhopeA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — United Medical Doctors, MurrietaA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants — Loma Linda University health, Loma LindaMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonA Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease — Investigational Site Number: 8400024, TucsonTestosterone Treatment in Men With Chronic Kidney Disease — Saint Louis Univeristy, St LouisEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborVECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease — TLC Clinical Research Inc - Los Angeles, Los AngelesA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis — Arkansas Children's (IP Address), Little RockUpadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis — University of Michigan, Ann ArborMoving Beyond Inflammation as a Therapeutic Target for Crohn's Disease — Cedars-Sinai Medical Center, Beverly HillsSAfety of Regional Citrate Anticoagulation (SARCA Study) — John L. McClellan Memorial Veterans' Hospital, Little RockA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Gastro Care Institute, LancasterEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Apogee Clinical Research, HuntsvilleOpen-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD — Digestive & Liver Center of Florida, OrlandoThe Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institutes of Health Clinical Center, BethesdaA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis — Site 024, Canoga ParkA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) — Digestive Health Specialists ( Site 5064), DothanA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease — Cedars Sinai Medical Center, Los AngelesPatient-driven Management of BP in CKD — Iowa City VA Health Care System, Iowa City, IA, Iowa CityStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD — New York University Langone Health, New YorkA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Gastro Care Institute, LancasterSafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkA Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — University Of Alabama, BirminghamA Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting — Gastro Health Research- St. Vincents East, BirminghamA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Dermatology Research Associates - 300204025, Los AngelesObe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) — State University of New York Upstate Medical Center (SUNY), SyracuseHB-adMSCs for the Treatment of Crohn's Disease — Hope Biosciences Research Foundation, Sugar LandA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease — Clinnova Research, AnaheimDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.Breakthrough - T1DM and Chronic Kidney Disease — The University of Chicago, ChicagoA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Research Site, PhoenixCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease — UCSF Benioff Children's Hospital - Oakland /ID# 262217, OaklandA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamBeta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, AustinA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyDouble-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — National Institutes of Health Clinical Center, BethesdaA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixPatient Preference for Subcutaneous vs. Intravenous Immune Therapy — UPMC Hillman Cancer Center, PittsburghFeasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis — University of Michigan, Ann ArborREgulatory T Cell Therapy to Achieve Immunosuppression REduction — Mayo Clinic in Arizona, PhoenixA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — ALS Global, IrvingA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgA Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease — Mirador Therapeutics Selected Site, BirminghamA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) — Nkarta Investigational Site, Little RockA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — HonorHealth Research and Innovation Institute, ScottsdaleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Onyx Clinical Research - Site Number: 8400021, PeoriaLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Mayo Clinic in Arizona - Scottsdale, ScottsdaleProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las VegasEquol and Vascular Function in Women With Chronic Kidney Disease — University of Colorado Anschutz Medical Campus, AuroraA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — Sl0044 50058, AvondaleA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia — R1 Therapeutics Clinical Trial Site, HuntsvilleA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants — US06-0, La Palma

Showing the 150 nearest — narrow your filters for fewer, closer studies.